Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.0% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−397.8%−2826.8%522.6%−47310.8%
ROIC0.0%0.0%0.0%0.0%

Debt

It holds more cash than debt: net debt is −0.18× a year’s EBITDA.

Net debt / EBITDA
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Net debt / EBITDA2.7×2.3×0.8×−0.2×

Cash cycle, in days

Customers pay in 0 days and suppliers are paid in 219. Suppliers fund 219 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle−1−4133−219
Days to pay suppliers13413894219
Days to be paid133971270

Per share, from Q4 FY25

Since Q4 FY25, per share: revenue has fallen 14.9%.

RevenueBook value
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue1.0×1.1×1.1×0.9×
Book value1.0×−0.3×−1.7×−1.8×
Sep '26 From the 10-Q filed 13 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
2 2 2 2

+8 more TTM periods

ROE
(47,310.78%) 522.58% (2,826.83%) (397.80%)
ROA
(71.43%) (103.88%) (92.86%) (74.11%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(217.54%) (301.98%) (161.47%) (118.61%)
Average Days of Receivables
0.00 126.57 96.71 132.92
Free Cash Flow per Share
(0.18) (0.20) (0.16) (0.17)
Free Cash Flow
(7.04) (7.40) (5.72) (5.70)
Other line items
Cash ROIC
272.94% (101.10%) (51.30%) (38.50%)
Accounts Receivable Turnover
0.00 3.68 6.07 4.46
Accounts Payable Turnover
1.86 4.10 3.73 3.48
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
219.11 93.54 137.50 134.05
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
54.98% 48.37% 56.09% 69.72%
Selling, General and Administrative Expense of Revenue
199.03% 162.38% 155.49% 186.44%
Share Based Compensation of Revenue
20.02% 17.05% 22.18% 30.10%
Interest Coverage
— (16.62) (15.74) (15.78)
Operating CF/Net income
1.00 0.97 0.78 0.77
Depreciation/Fixed assets
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.08 0.10 0.10 0.09
Operating CF per Share
(0.18) (0.20) (0.16) (0.17)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated 13 Nov 2026